Add-on Acquisition • Life Science

Cell Media Acquires Catapult Therapy TCR

On June 20, 2017, Cell Media acquired life science company Catapult Therapy TCR

Acquisition Context

This is Cell Media’s 1st transaction in the Life Science sector.
This is Cell Media’s 1st transaction in the United Kingdom.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	June 20, 2017
Target	Catapult Therapy TCR
Sector	Life Science
Buyer(s)	Cell Media
Deal Type	Add-on Acquisition

Target Company

Catapult Therapy TCR

London, United Kingdom

Catapult Therapy TCR Ltd. is a company formed by the cell and gene therapy catapult with uclb and imperial innovations to develop a novel cell therapy approach to the treatment of acute myeloid leukaemia.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Cell Media

Perth, Australia

Category	Company
Sector	Life Science

DESCRIPTION

Cell Media is a developer of therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs).

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: United Kingdom	1 of 1
Year: 2017	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - United Kingdom M&A - 2017 M&A